Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

Immunotherapy - 1 Jun 2016

Aya Francisco, Fernández-Martínez Aranzazu, Gaba Lydia, Victoria Iván, Tosca Mónica, Carrera Cristina, Prat Aleix, Arance Ana

Abstract excerpt

Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to treatment-related grade 3 colitis and was subsequently treated with the anti-programmed cell death 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Colitis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA-4 Antigen

Share to Drug-Related Side Effects and Adverse Reactions

Share to Ipilimumab

Share to Neoplasm Metastasis

Share to Programmed Cell Death 1 Receptor

Share to Quality of Life

Source

Identifiers

PMID: 27115320
DOI: 10.2217/imt-2015-0025

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.PMID 27115320Read ↗

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.Semantic proximity Read ↗

Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.Semantic proximity Read ↗

Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.Semantic proximity Read ↗

Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.Semantic proximity Read ↗

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.Semantic proximity Read ↗

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.Semantic proximity Read ↗

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read ↗

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.